The BCR-ABL1 fusion protein resulting from t(9;22) activates the PI3K/mTOR pathway directly in both chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) ALL (17). This evidence concerns the gene MTOR and chronic myelogenous leukemia, BCR-ABL1 positive.